Partner Article

Quantum Pharma sees ‘good strategic progress’ during year of acquisitions

AIM-listed Drug manufacturer, Quantum Pharma has reported ‘good strategic progress’ across all areas of the business in the last six months..

The County Durham-based company said performance remains in line with market expectations for the year to 31 January 2016.

As previously announced, Quantum completed the acquisitions of the Lamda group of companies and NuPharm Group during this period.

Colonis, the specialist pharmaceutical product development business, continues to grow its pipeline and submissions to the relevant authorities and to progress its product launch programme.

Andrew Scaife, Chief Executive Officer of Quantum Pharma Plc, said: “The first six months of the financial year have been a busy period at Quantum Pharma. We successfully completed the strategic acquisitions of Lamda and NuPharm and the integration of both these companies into the Group is ongoing. In addition, pleasingly, a number of the business units have had record half years.”

There are currently over 70 regulated products (licensed products and medical devices) in the pipeline with a number of other opportunities to increase the pipeline further during this financial year.

Quantum has also announced plans to launch 11 more regulated products by the end of the financial year. There are also a number of active opportunities for additional regulated products to be brought into the pipeline and launched this year.

Andrew continued: “Progress continues to be made on the Colonis pipeline, and we look forward to announcing a number of further regulated product launches during the second half of the year.

“As is sometimes the case, the regulatory process on certain products is taking slightly longer than anticipated, however we are confident of securing licences for all products in assessment with the MHRA and other regulators. We look forward to presenting our half year results in October.”

This was posted in Bdaily's Members' News section by Ellen Forster .